WHO ICTRP trial
The ConvP COVig PKPD study: an investigation for the use of plasma or antibodies…
EUCTR2021-000864-32-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2021-000864-32-NL |
|---|---|
| Public title | The ConvP COVig PKPD study: an investigation for the use of plasma or antibodies against the novel coronavirus (SARS-CoV-2) |
| Scientific title | A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulines - ConvP COVig PKPD study |
| Primary sponsor | Erasmus MC |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | COVID-19 or protective effect against in B-cell depleted patients or vaccination non-responders MedDRA version: 23.1 Level: LLT Classification code 10084464 Term: COVID-19 immunization System Organ Class: 100000004865 ;Therapeutic area… |
| Interventions | Trade Name: Nanogam 100 mg/ml Pharmaceutical Form: Solution for infusion |
| Registration date | Mar 19, 2021 |
| Target size | 104 |
| Secondary IDs | NL76798.078.21 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: